Context: Extraordinary advances in the fields of polymer nanoparticle (nano) drug technology, nanomedicines, nanostructures, and nanoscale sciences have played a key role in the healthcare system. New nanodrug complexes have exceptional pharmacological properties with large surface areas that encourage a formulated medication to distribute, absorb, and produce the desired clinical effects.
Objective: The current study aimed to review the latest development in the field of nanodrug particles, theranostic, use of noninvasive techniques, and enhancement of retention of nano-theranostic formulations. That helps to develop the innovative pharmaceutical dosage forms.
Setting: The latest published data extracted from search engines PubMed, Scopus, Medline, Wolfram Alpha, BASE, Science.gov, Semantic Scholar, Education Resources Information Center, Microsoft Academic, ResearchGate, RefSeek, WorldWideScience, arXiv, Microsoft Academic Search, Google Books, JSTOR, Scirus, Social Science Research Network, Bioline International, SciELO, MetaCrawler, PLOS One, Google Scholar, and Infotopia.
Design: The metadata of clinical trials, retrospective, prospective and case control studies collected from the peer review research/ review articles. The aforesaid search engines used to explore the latest information published in ≤200 research studies. the key words Nanomedicines, nanostructure, nanoscale sciences and clinical development run into the system to obtain more specific information. The final data was analyzed, interpreted and narrated for his study.
Result: The precisely use of nanodrug for targeted disease produced considerable clinical results. Particularly the designed therapeutic nanoparticle formulations help to reduce the excretion, prolong blood circulation to increase accumulation at a targeted site and increase the therapeutic effects.
Conclusions: The nanodrug complexes are successfully translated into several modern medications. The new and innovative nanodrug can potentially be used precisely and correctly to diagnose and treat the terminally ill patients. However, the developed nanodrug complexes, whether they are carriers or therapeutic agents, need thorough physiochemical, pharmacological, and immunological characterization before actual use in clinical practice in different human population of the world.